Skip to main content

Table 5 Results of cost-effectiveness analysis for original, worst-case and best-case scenarios (with 95% CI)

From: Cost-effectiveness of a whole-area testing pilot of asymptomatic SARS-CoV-2 infections with lateral flow devices: a modelling and economic analysis study

Scenario

QALYs gained

Net costs (£)

ICER per QALY gained (£)

NMB (£)

ROI (£)

Original

108 ( 80—143)

231,188 ( 33,3188—122,814)

2143 ( 860—4175)

6,240,594 (4,455,127 – 8,448,442)

12 ( 9—16)

Worst case scenario

64 ( 50—85)

354,906 ( 412,991—282,420)

5562 ( 3339—8280)

3,473,831 ( 2,579,534 – 4,792,587)

7 ( 5—9)

Best case scenario

262 ( 205—336)

-159,335 ( 7,124—-412,217)

-608 ( -1228—35)

15,866,328 (12,296,102 – 20,546,837)

31 ( 24—40)